tiprankstipranks
Trending News
More News >

Unity Biotechnology downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Unity Biotechnology (UBX) to Neutral from Buy with a price target of $2, down from $4. The firm cites the company’s management transitions and forthcoming platform direction for the downgrade. Following the previously announced primary endpoint miss for the Phase 2B ASPIRE study comparing UBX1325 and aflibercept in diabetic macular edema patients not achieving non-inferiority at the average of weeks 20 and 24 primary analysis, H.C. Wainwright downgraded Unity.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue